John Libbey Eurotext

European Cytokine Network

Increased serum IL-17A and Th2 cytokine levels in patients with severe uncontrolled asthma Volume 28, numéro 1, March 2017

  • [1] Wenzel S.E. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18:716-725.
  • [2] Haldar P., Pavord I.D., Shaw D.E. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178:218-224.
  • [3] Lotvall J., Akdis C.A., Bacharier L.B. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127:355-360.
  • [4] Szefler S.J., Wenzel S., Brown R. Asthma outcomes: biomarkers. J Allergy Clin Immunol. 2012;129:S9-23.
  • [5] Hanania N.A., Wenzel S., Rosen K. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187:804-811.
  • [6] Bjermer L., Alving K., Diamant Z. Current evidence and future research needs for FeNO measurement in respiratory diseases. Respir Med. 2014;108:830-841.
  • [7] Trevor J.L., Deshane J.S. Refractory asthma: mechanisms, targets, and therapy. Allergy. 2014;69:817-827.
  • [8] Pukelsheim K., Stoeger T., Kutschke D., Ganguly K., Wjst M. Cytokine profiles in asthma families depend on age and phenotype. PLoS One. 2010;5:e14299.
  • [9] Bettiol J., Sele J., Henket M. Cytokine production from sputum cells after allergenic challenge in IgE-mediated asthma. Allergy. 2002;57:1145-1150.
  • [10] Wong C.K., Ho C.Y., Ko F.W. Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-gamma, IL-4, IL-10 and IL-13) in patients with allergic asthma. Clin Exp Immunol. 2001;125:177-183.
  • [11] Fahy J.V. Type 2 inflammation in asthma – present in most, absent in many. Nat Rev Immunol. 2015;15:57-65.
  • [12] Lloyd C.M., Hessel E.M. Functions of T cells in asthma: more than just T(H)2 cells. Nat Rev Immunol. 2010;10:838-848.
  • [13] Souwer Y., Szegedi K., Kapsenberg M.L., de Jong E.C. IL-17 and IL-22 in atopic allergic disease. Curr Opin Immunol. 2010;22:821-826.
  • [14] Ciprandi G., De Amici M., Murdaca G. Serum interleukin-17 levels are related to clinical severity in allergic rhinitis. Allergy. 2009;64:1375-1378.
  • [15] Agache I., Ciobanu C., Agache C., Anghel M. Increased serum IL-17 is an independent risk factor for severe asthma. Respir Med. 2010;104:1131-1137.
  • [16] Doe C., Bafadhel M., Siddiqui S. Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD. Chest. 2010;138:1140-1147.
  • [17] Wang Y.H., Wills-Karp M. The potential role of interleukin-17 in severe asthma. Curr Allergy Asthma Rep. 2011;11:388-394.
  • [18] Newcomb D.C., Peebles R.S. Jr. Th17-mediated inflammation in asthma. Curr Opin Immunol. 2013;25:755-760.
  • [19] Chesne J., Braza F., Mahay G., Brouard S., Aronica M., Magnan A. IL-17 in severe asthma. Where do we stand? Am J Respir Crit Care Med. 2014;190:1094-1101.
  • [20] Chambers E.S., Nanzer A.M., Pfeffer P.E. Distinct endotypes of steroid-resistant asthma characterized by IL-17A(high) and IFN-gamma(high) immunophenotypes: potential benefits of calcitriol. J Allergy Clin Immunol. 2015;138:628-637.
  • [21] Wilson R.H., Whitehead G.S., Nakano H., Free M.E., Kolls J.K., Cook D.N. Allergic sensitization through the airway primes Th17-dependent neutrophilia and airway hyperresponsiveness. Am J Respir Crit Care Med. 2009;180:720-730.
  • [22] Wakashin H., Hirose K., Maezawa Y. IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice. Am J Respir Crit Care Med. 2008;178:1023-1032.
  • [23] Alyasin S., Karimi M.H., Amin R., Babaei M., Darougar S. Interleukin-17 gene expression and serum levels in children with severe asthma. Iran J Immunol. 2013;10:177-185.
  • [24] Zhou X., Fragala M.S., McElhaney J.E., Kuchel G.A. Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research. Curr Opin Clin Nutr Metab Care. 2010;13:541-547.
  • [25] Sullivan K.E., Cutilli J., Piliero L.M. Measurement of cytokine secretion, intracellular protein expression, and mRNA in resting and stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol. 2000;7:920-924.
  • [26] Bienvenu J., Monneret G., Fabien N., Revillard J.P. The clinical usefulness of the measurement of cytokines. Clin Chem Lab Med. 2000;38:267-285.
  • [27] Rabinowitz J., Petros W.P., Stuart A.R., Peters W.P. Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support. Blood. 1993;81:2452-2459.
  • [28] Abbal C., Persi L., Bousquet J., Yssel H., Pene J. Effect of bronchial allergen challenge on in vitro cytokine release by peripheral blood mononuclear cells of atopic patients. Allergy. 1998;53:945-950.
  • [29] Liang Z., Liu L., Zhao H. A systemic inflammatory endotype of asthma with more severe disease identified by unbiased clustering of the serum cytokine profile. Medicine. 2016;95:e3774.
  • [30] Lambrecht B.N., Hammad H. The immunology of asthma. Nat Immunol. 2015;16:45-56.
  • [31] Moore W.C., Meyers D.A., Wenzel S.E. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181:315-323.
  • [32] Siroux V., Basagana X., Boudier A. Identifying adult asthma phenotypes using a clustering approach. Eur Respir J. 2011;38:310-317.
  • [33] Woodruff P.G., Modrek B., Choy D.F. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180:388-395.
  • [34] Vazquez-Tello A., Halwani R., Hamid Q., Al-Muhsen S. Glucocorticoid receptor-beta up-regulation and steroid resistance induction by IL-17 and IL-23 cytokine stimulation in peripheral mononuclear cells. J Clin Immunol. 2013;33:466-478.
  • [35] Zijlstra G.J., Ten Hacken N.H., Hoffmann R.F., van Oosterhout A.J., Heijink I.H. Interleukin-17A induces glucocorticoid insensitivity in human bronchial epithelial cells. Eur Respir J. 2012;39:439-445.
  • [36] Chakir J., Shannon J., Molet S. Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression. J Allergy Clin Immunol. 2003;111:1293-1298.
  • [37] Nanzer A.M., Chambers E.S., Ryanna K. Enhanced production of IL-17A in patients with severe asthma is inhibited by 1alpha,25-dihydroxyvitamin D3 in a glucocorticoid-independent fashion. J Allergy Clin Immunol. 2013;132:297-304.
  • [38] Al-Ramli W., Al Samri M., Hamid Q. Th-17 cell-related cytokines’ potential role in the pathogenesis of severe asthma. J Asthma. 2008;45:41-44.
  • [39] Kim H.Y., Lee H.J., Chang Y.J. Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nat Med. 2014;20:54-61.
  • [40] Irvin C., Zafar I., Good J. Increased frequency of dual-positive TH2/TH17 cells in bronchoalveolar lavage fluid characterizes a population of patients with severe asthma. J Allergy Clin Immunol. 2014;134:1175-86.
  • [41] Choy D.F., Hart K.M., Borthwick L.A. TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci Transl Med. 2015;7:301ra129.
  • [42] Cosmi L., Liotta F., Maggi E., Romagnani S., Annunziato F. Th17 cells: new players in asthma pathogenesis. Allergy. 2011;66:989-998.
  • [43] Wang Y.H., Voo K.S., Liu B. A novel subset of CD4(+) T(H)2 memory/effector cells that produce inflammatory IL-17 cytokine and promote the exacerbation of chronic allergic asthma. J Exp Med. 2010;207:2479-2491.
  • [44] Peters M.C., Mekonnen Z.K., Yuan S., Bhakta N.R., Woodruff P.G., Fahy J.V. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol. 2014;133:388-394.
  • [45] Seys S.F., Grabowski M., Adriaensen W. Sputum cytokine mapping reveals an ‘IL-5, IL-17A, IL-25-high’ pattern associated with poorly controlled asthma. Clin Exp Allergy. 2013;43:1009-1017.
  • [46] Cheng D., Xue Z., Yi L. Epithelial interleukin-25 is a key mediator in Th2-high, corticosteroid-responsive asthma. Am J Respir Crit Care Med. 2014;190:639-648.
  • [47] Zhao Y., Yang J., Gao Y.D., Guo W. Th17 immunity in patients with allergic asthma. Int Arch Allergy Immunol. 2010;151:297-307.
  • [48] Kinyanjui M.W., Shan J., Nakada E.M., Qureshi S.T., Fixman E.D. Dose-dependent effects of IL-17 on IL-13-induced airway inflammatory responses and airway hyperresponsiveness. J Immunol. 2013;190:3859-3868.
  • [49] Barlow J.L., Flynn R.J., Ballantyne S.J., McKenzie A.N. Reciprocal expression of IL-25 and IL-17A is important for allergic airways hyperreactivity. Clin Exp Allergy. 2011;41:1447-1455.
  • [50] Mizutani N., Nabe T., Yoshino S. IL-17A promotes the exacerbation of IL-33-induced airway hyperresponsiveness by enhancing neutrophilic inflammation via CXCR2 signaling in mice. J Immunol. 2014;192:1372-1384.
  • [51] Ji X., Li J., Xu L. IL4 and IL-17A provide a Th2/Th17-polarized inflammatory milieu in favor of TGF-beta1 to induce bronchial epithelial-mesenchymal transition (EMT). Int J Clin Exp Pathol. 2013;6:1481-1492.
  • [52] Shannon J., Ernst P., Yamauchi Y. Differences in airway cytokine profile in severe asthma compared to moderate asthma. Chest. 2008;133:420-426.
  • [53] Liu L., Jarjour N.N., Busse W.W., Kelly E.A. Enhanced generation of helper T type 1 and 2 chemokines in allergen-induced asthma. Am J Respir Crit Care Med. 2004;169:1118-1124.
  • [54] Saraiva M., O’Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10:170-181.
  • [55] Koponen P., Nuolivirta K., Virta M., Helminen M., Hurme M., Korppi M. Polymorphism of the rs1800896 IL10 promoter gene protects children from post-bronchiolitis asthma. Pediatr Pulmonol. 2014;49:800-806.
  • [56] Ghannam S., Pene J., Moquet-Torcy G., Jorgensen C., Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol. 2010;185:302-312.
  • [57] Zhang Y.L., Luan B., Wang X.F. Peripheral blood MDSCs, IL-10 and IL-12 in children with asthma and their importance in asthma development. PLoS One. 2013;8:e63775.
  • [58] Raeiszadeh Jahromi S., Mahesh P.A., Jayaraj B.S. Serum levels of IL-10, IL-17F and IL-33 in patients with asthma: a case-control study. J Asthma. 2014;51:1004-1013.
  • [59] Anderson G.P. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet. 2008;372:1107-1119.
  • [60] Haldar P., Brightling C.E., Hargadon B. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973-984.